7^th Global Cardiovascular Research and Clinical Cardiology October 30-31, 2024 Chicago, USA

HEART CONGRESS-2024 aims to provide a platform for networking, knowledge exchange, and collaboration among professionals from diverse backgrounds involved in the prevention, diagnosis, and treatment of cardiovascular diseases. Whether you're a seasoned expert or a newcomer to the field, there are opportunities to learn, engage, and contribute to advancements in cardiovascular care and research.

Clinical Trials and Epidemiology: It focuses on clinical trials investigating new treatments, diagnostic tools, and preventive measures for cardiovascular diseases. It can also cover epidemiological studies exploring the prevalence, risk factors, and outcomes of cardiovascular conditions.

• Pharmacological Trials:
• Device Trials:
• Preventive Trials
• Diagnostic Trials:

Cardiovascular Imaging and Diagnostics: It advances in imaging techniques such as echocardiography, cardiac MRI, CT angiography, and nuclear cardiology. It can also cover developments in diagnostic tools for early detection and risk stratification of heart disease.

• Echocardiography
• Cardiac MRI (Magnetic Resonance Imaging)
• CT (Computed Tomography) Angiography
• Nuclear Cardiology
• Multimodality Imaging

Interventional Cardiology and Cardiac Surgery: It can feature the latest techniques and technologies in interventional cardiology, including coronary angioplasty, stenting, structural heart interventions, and minimally invasive cardiac surgery. Topics may include advancements in balloon angioplasty, drug-eluting stents, bioresorbable scaffolds, and drug-coated balloons. Discussions may cover procedural approaches, lesion preparation strategies, stent optimization techniques, and long-term outcomes.

• Complex Coronary Interventions
• Structural Heart Interventions
• Peripheral Vascular Interventions
• Electrophysiology Procedures
• Minimally Invasive Cardiac Surgery
• Hybrid Procedures

Heart Failure and Cardiomyopathies: It can focus on heart failure prevention, diagnosis, and management strategies, including pharmacotherapy, device therapy (e.g., pacemakers, implantable cardioverter-defibrillators), and advanced heart failure therapies (e.g., heart transplantation, ventricular assist devices).

Evaluation and management of patients with advanced heart failure refractory to conventional therapies. This includes heart transplantation, mechanical circulatory support (e.g., LVADs, temporary mechanical support devices), and palliative care. Topics may include patient selection criteria, perioperative management, long-term outcomes, and quality of life considerations.

• Heart Failure Prevention
• Heart Failure Diagnosis
• Pharmacological Therapy for Heart Failure
• Advanced Heart Failure Therapies

Arrhythmias and Electrophysiology: This track can cover the diagnosis and treatment of cardiac arrhythmias, including atrial fibrillation, ventricular tachycardia, and sudden cardiac death. Topics may include catheter ablation, antiarrhythmic drugs, implantable devices, and risk stratification. Diagnoswis and management of ventricular arrhythmias, including ventricular tachycardia (VT) and ventricular fibrillation (VF). This includes risk stratification, antiarrhythmic drug therapy, catheter ablation techniques, and implantable cardioverter-defibrillator (ICD) therapy. Discussions may also cover inherited arrhythmia syndromes (e.g., long QT syndrome, Brugada syndrome) and sudden cardiac death risk assessment.

• Ventricular Arrhythmias
• Catheter Ablation Techniques
• Antiarrhythmic Drug Therapy
• Implantable Devices

Preventive Cardiology and Lifestyle Medicine: This track can address strategies for cardiovascular disease prevention, including lifestyle modifications (e.g., diet, exercise, smoking cessation), risk assessment, and population health interventions. Guidance on the prescription of exercise and physical activity for cardiovascular health promotion and disease prevention. This includes recommendations for aerobic exercise, resistance training, flexibility exercises, and balance training. Topics may also include exercise intensity, frequency, duration, and progression, as well as considerations for special populations (e.g., older adults, individuals with chronic conditions).

• Nutrition and Dietary Interventions
• Smoking Cessation Programs

Pediatric and Congenital Heart Disease: This track can focus on the diagnosis and management of congenital heart defects and acquired heart diseases in children and adolescents, including surgical and non-surgical interventions, long-term outcomes, and transition to adult care. This includes discussions on the embryology and pathophysiology of CHDs, genetic and environmental risk factors, and prenatal screening and diagnosis.

• Diagnostic Modalities in Pediatric Cardiology
• Acquired Heart Diseases in Pediatric Population
• Long-Term Follow-Up and Outcomes

Cardiovascular Rehabilitation and Secondary Prevention: This track can cover programs and interventions aimed at optimizing recovery and improving outcomes for patients with cardiovascular disease, including cardiac rehabilitation, risk factor management, and psychosocial support. It includes exercise testing, individualized exercise prescriptions, aerobic training, resistance training, flexibility exercises, and balance training. Topics may also cover exercise safety considerations, monitoring techniques, and exercise adherence strategies.

• Nutritional Counseling and Dietary Interventions
• Psychosocial Support and Behavioral Counseling

Cardio-Oncology: This track can focus on the intersection of cardiovascular disease and cancer, including the cardiotoxic effects of cancer therapies (chemotherapy, radiation), risk stratification, prevention, and management of cardiovascular complications in cancer patients and survivors. trategies for cardiovascular risk assessment and risk stratification in cancer patients before, during, and after cancer treatment. This includes pre-treatment cardiovascular evaluation, assessment of baseline cardiac function, identification of pre-existing cardiovascular risk factors, and monitoring for cardiotoxicity during cancer therapy.

Cardiovascular Pharmacology and Drug Development: This track can cover novel pharmacological agents for the prevention and treatment of cardiovascular diseases, including mechanisms of action, efficacy, safety profiles, and clinical trial outcomes.

Cardiovascular Genetics and Precision Medicine: This track can explore the role of genetic factors in cardiovascular diseases, including hereditary cardiomyopathies, familial hypercholesterolemia, and genetic predispositions to arrhythmias and coronary artery disease. It can also address the application of precision medicine approaches in risk prediction, diagnosis, and treatment selection.

Vascular Biology and Peripheral Artery Disease: This track can focus on the pathophysiology of vascular diseases, including atherosclerosis, peripheral artery disease (PAD), and vasculitis. Topics may include endothelial dysfunction, vascular inflammation, biomarkers, imaging modalities, and novel therapies.

Women's Cardiovascular Health: This track can address sex-specific differences in the epidemiology, pathophysiology, diagnosis, and management of cardiovascular diseases in women. It can also cover pregnancy-related cardiovascular complications, such as gestational hypertension, preeclampsia, and peripartum cardiomyopathy.

Cardiovascular Imaging in Structural Heart Disease: This track can highlight advances in cardiovascular imaging modalities for the assessment of structural heart diseases, including valvular heart disease, congenital heart defects, and structural interventions (e.g., transcatheter aortic valve replacement, mitral valve repair).

Cardiovascular Biomarkers and Risk Assessment: This track can focus on emerging biomarkers for the early detection, risk stratification, and prognosis of cardiovascular diseases. Topics may include circulating biomarkers (e.g., cardiac troponins, natriuretic peptides), imaging-based biomarkers, and novel risk prediction models.